Novel Tc(CO)3 Complexes with WAY-100635 Moiety in the Development of 5-HT1A Receptor Imaging Agent

The significant studies have been made in the past two decades for developing new 99mTc-based brain imaging agent, since two brain perfusion agents(ECD(L,L - Ethylcysteinate Dimer) and HMPAO (Hexamethyl Propyleneamine Ocime)) were developed. Recently, many efforts are focusing on the development of radiopharmaceuticals specific for brain receptor or brain binding-site, which may lead to improved clinical tools for nuclear medicine. Futhermore, Since 5-HT1A receptors are implicated in several neuropsychiatric disorders, their visualization in the human brain has been studied with PET and SPECT. Several approaches with 5-HT1A antagonist ([11C] WAY-100635) have been pursued for PET imaging agents. However, the short half life of carbon-11 limits these radio pharmaceuticals from being utilized in a local imaging procedure despite their high specific activity for in vivo application. Thus, we have focused on 5-HT1A and its antagonist by application of the technetium tricarbonyl technology. We suggest herein a synthesizing method for arylpiperazine derivatives and discussed here the physical properties of their 99mTc(CO)+3 complexes